2025-05-19Niranjan Ghatule
This article covers Morgan Stanley’s insights on Q4 earnings based on the results declared so far. It highlights key trends in revenue growth, EBITDA margins, sector performance, and how companies across Nifty, mid-cap, and small-cap segments have fared against market estimates.
View more
2025-05-07Niranjan Ghatule
Shares of Aarti Drugs surged 20% to hit the upper circuit at Rs 420 following strong Q4 FY24 results and favorable legal relief. The company reported a sharp rise in revenue and profit continues its Rs 600 crore capex-driven growth journey. With leadership in over 50 API molecules and a robust global footprint, Aarti Drugs is positioned for long-term expansion.
View more
Your experience on this site will be improved by allowing cookies
Cookie Policy